NASDAQ:NEUP Neuphoria Therapeutics (NEUP) Stock Price, News & Analysis $3.73 0.00 (0.00%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$3.74 +0.01 (+0.27%) As of 09/11/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Neuphoria Therapeutics Stock (NASDAQ:NEUP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Neuphoria Therapeutics alerts:Sign Up Key Stats Today's Range$3.72▼$3.7850-Day Range$3.30▼$3.9852-Week Range$3.19▼$21.40Volume23,039 shsAverage Volume48,170 shsMarket Capitalization$20.14 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingReduce Company Overview Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA. Read More Neuphoria Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreNEUP MarketRank™: Neuphoria Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 640th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingReduce Consensus RatingNeuphoria Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialNeuphoria Therapeutics has a consensus price target of $7.00, representing about 87.7% upside from its current price of $3.73.Amount of Analyst CoverageNeuphoria Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Neuphoria Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Neuphoria Therapeutics are expected to grow in the coming year, from ($4.07) to ($2.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neuphoria Therapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neuphoria Therapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuphoria Therapeutics has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Neuphoria Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.21% of the float of Neuphoria Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeuphoria Therapeutics has a short interest ratio ("days to cover") of 0.95, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neuphoria Therapeutics has recently increased by 53.78%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuphoria Therapeutics does not currently pay a dividend.Dividend GrowthNeuphoria Therapeutics does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment0.93 News SentimentNeuphoria Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Neuphoria Therapeutics this week, compared to 2 articles on an average week. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Neuphoria Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders1.50% of the stock of Neuphoria Therapeutics is held by insiders.Percentage Held by Institutions15.90% of the stock of Neuphoria Therapeutics is held by institutions.Read more about Neuphoria Therapeutics' insider trading history. Receive NEUP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuphoria Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NEUP Stock News HeadlinesReviewing Moderna (NASDAQ:MRNA) and Neuphoria Therapeutics (NASDAQ:NEUP)September 11 at 2:14 AM | americanbankingnews.comNeuphoria Therapeutics Inc Ordinary Shares NEUPAugust 14, 2026 | morningstar.comMHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 13 at 1:00 AM | Stansberry Research (Ad)Neuphoria Therapeutics Inc (NEUP)August 8, 2026 | investing.comThe M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—NRIM, NEUP, SAFT, and RMAXJuly 30, 2026 | globenewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—PBCO, NEUP, SAFT, and PFLCJuly 28, 2026 | globenewswire.comNEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its ShareholdersJuly 24, 2026 | businesswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP)July 24, 2026 | prnewswire.comSee More Headlines NEUP Stock Analysis - Frequently Asked Questions How have NEUP shares performed this year? Neuphoria Therapeutics' stock was trading at $3.88 at the beginning of the year. Since then, NEUP stock has decreased by 3.9% and is now trading at $3.73. How were Neuphoria Therapeutics' earnings last quarter? Neuphoria Therapeutics Inc. (NASDAQ:NEUP) released its quarterly earnings results on Friday, May, 15th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.47. Who are Neuphoria Therapeutics' major shareholders? Top institutional investors of Neuphoria Therapeutics include ADAR1 Capital Management LLC (0.56%) and Merck & Co. Inc. (0.19%). View institutional ownership trends. How do I buy shares of Neuphoria Therapeutics? Shares of NEUP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/15/2026Today9/13/2026Next Earnings (Estimated)10/05/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (10m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 NEUP's financial health is in the Yellow zone, according to TradeSmith. NEUP has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NEUP Previous SymbolNASDAQ:NEUP CIK1191070 Webwww.bionomics.com.au Phone61-8-8150-7400FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Neuphoria Therapeutics$7.00 High Price Target$7.00 Low Price Target$7.00 Potential Upside/Downside+87.7%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($11.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$370 thousand Net MarginsN/A Pretax Margin-40.58% Return on Equity-76.93% Return on Assets-54.76% Debt Debt-to-Equity RatioN/A Current Ratio14.31 Quick Ratio14.31 Sales & Book Value Annual Sales$15.65 million Price / Sales1.29 Cash Flow$0.16 per share Price / Cash Flow23.93 Book Value$10.11 per share Price / Book0.37Miscellaneous Outstanding Shares5,400,000Free Float5,324,000Market Cap$20.14 million OptionableN/A Beta0.75 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:NEUP) was last updated on 9/13/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuphoria Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuphoria Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
